arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CorMedix Inc.

CRMD
$7.43 ▼ -0.06 (-0.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
94
Health
Excellent
Bullish
auto_awesome

Analytical Summary

CorMedix Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth 617.0%
Op. Margin 48.2%
ROIC 40.3%
FCF / Share None
Trailing P/E 3.3x
Price / Book 1.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$311.71M
↑ +617.0%
Net Income Profit after all expenses
$163.06M
↑ +1009.4%
Operating Margin Operating profit as % of sales
48.2%
↑ +193.7% 97th
FCF / Share Free cash flow per share
$-0.86
↓ -13.2%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
98
Returns
96
Financial Health
100
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 71 quarters